NasdaqGS:VIRBiotechs
Vir Biotechnology (VIR) Valuation After Astellas Partnership And New VIR 5500 Trial Milestone
Vir Biotechnology (VIR) is back in focus after dosing the first patient in a Phase 1 expansion cohort for VIR-5500 and after closing a global development and commercialization agreement with Astellas for the same asset.
See our latest analysis for Vir Biotechnology.
Vir's recent VIR-5500 milestones and the Astellas deal come after a sharp rebound, with a 90 day share price return of 70.46% and a 1 year total shareholder return of 87.82%, although 3 and 5 year total shareholder returns remain...